The following message is from BioCanRx.
“As some of you are aware, BioCanRx – Canada’s Immunotherapy Network, was awarded funding through the Government of Canada’s Strategic Science Fund for the period of 2024-2029.
BioCanRx is a network of scientists, highly qualified personnel, clinicians, cancer stakeholders, NGOs and industry partners working together to accelerate the development of innovative cancer immunotherapy therapeutics. Since 2015, BioCanRx has taken an integrated, synergistic approach to cancer therapy development with a common goal for creating a trans-Canadian, multi-disciplinary network of clinicians and scientists to rapidly develop biotherapeutics for cancer therapy. We play a unique role in the ecosystem investing in world-class translational research in the area of immune oncology to carry out our Mission of accelerating to the clinic the most promising cancer immunotherapies designed to save lives and enable a better quality of life to reach our Vision of turning all cancers into curable diseases. Learn more about BioCanRx here.
BioCanRx is asking you, the Canadian community engaging in, or looking to engage in, cancer immunotherapy research to help us define our research program priorities via a consultation survey.
We highly encourage responses from individuals who have previously interacted with our network, as well as those who are seeking to engage with us in the future.
We are seeking responses from:
– Researchers across the translational research spectrum (preclinical to early-phase clinical trials, and individuals studying clinical, social and economic and legal issues surrounding implementation and access to cancer immunotherapies)
– Trainees and other highly qualified personnel (e.g., clinical, research, technical or biomanufacturing personnel)
– Individuals with lived experience
– Representatives of a cancer charity, advocacy or research organization
– Industry partners
– Other stakeholders actively involved in expanding access to immunotherapies in Canada
We kindly ask that you fill out this survey, by Monday, April 8, 2024
We also ask you to share and promoting this survey with interested colleagues and other stakeholders.
Thank you for your participation,
John Bell, PhD | Scientific Director, BioCanRx
Stéphanie Michaud, PhD | President and CEO
Megan Mahoney, PhD | Director of Scientific Affairs and Training Programs